peptide vaccination induces profound changes in the immune system in patients with b-cell chronic lymphocytic leukemia
Clicks: 168
ID: 217659
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
168 views
37 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #30 of 46 articles by views in reviews on recent clinical trials
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus-leukemia effect) and <i>in vitro</i> (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8<sup>+</sup>CD103<sup>+</sup>, CD8<sup>+</sup>CD137<sup>+</sup> and IL-17 producing CD8<sup>+</sup> T cells (CD8<sup>+</sup>IL- -17<sup>+</sup>) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period. <i>(Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 161–167)
| Reference Key |
schmitt2011foliapeptide
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Michael Schmitt;Jacek Roliński;Anna Dmoszyńska;Paulina Własiuk;Krzysztof Giannopoulos |
| Journal | reviews on recent clinical trials |
| Year | 2011 |
| DOI |
10.5603/4158
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.